Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pomella is a **patented and proprietary standardized pomegranate (Punica granatum) fruit extract** developed by Verdure Sciences. It is standardized for high content of polyphenols—mainly **punicalagins**—and supports antioxidant activity by providing both these ellagitannins and their gut microbial metabolites, known as **urolithins**. The extract is chemically characterized for consistent levels of these marker compounds and is produced with rigorous quality and traceability controls. Pomella has been evaluated in clinical and preclinical research for its activities on **collagenase and matrix metalloproteinase (MMP) inhibition**, **antioxidant effects**, and potential benefits on **skin health, gut health, and prostate health**. Its mechanism of action is primarily through inhibition of collagen-degrading enzymes and modulation of ECM-related protein expression[1][6][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pomella.